To explore if these inhibitory receptors could be part of a signature that might be used as biomarkers, we normalized our results calculating the z-scores for CD85j, CD45 and CD48, and we also combined these z-scores to explore if the behavior of PBNK from ccRCC differs from HD. This evidence concerns the gene PTPRC and Huntington disease.